National Women’s Health Week, which we celebrate from May 10th-16th this year, is a time to highlight the importance of women’s health! In support of helping improve and prioritize women’s health, we want to draw attention to recently published data describing sex-differences in the management of recurrent pericarditis. Real-world data from the RESONANCE registry indicate that females were diagnosed with recurrent pericarditis sooner than males but, despite similar disease severity, experienced later escalation to second-line therapy, resulting in additional recurrences while remaining on first-line therapy. These findings underscore the need for heightened clinical vigilance and earlier adoption of evidence-based treatment escalation strategies, such as IL-1 pathway inhibition, to help ensure equitable and optimized care for recurrent pericarditis across sexes.
Kiniksa Pharmaceuticals
Biotechnology Research
Lexington, Massachusetts 32,236 followers
Relentless. Passionate. Focused.
About us
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. At Kiniksa, patients are at the heart of everything we do. Our Every Second Counts! mindset reflects our commitment to making a difference for people who are navigating the uncertainty and challenges of life-altering diseases. This is why our team is relentless in pursuing treatments that bring us closer to a better future for patients, every second of every day. We rely on an exceptional team to drive our mission of building a global, generational company. If you're passionate about making a meaningful impact, we’d love to hear from you. Kiniksa offers competitive benefits and dynamic career opportunities across our organization. We foster a culture of passion, innovation, and rapid execution to help fulfill our mission.
- Website
-
http://www.kiniksa.com
External link for Kiniksa Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Lexington, Massachusetts
- Type
- Public Company
- Founded
- 2015
Locations
-
Primary
Get directions
100 Hayden Ave
Lexington, Massachusetts 02421, US
-
Get directions
105 Piccadilly
Second Floor
London, England W1J 7NJ, GB
-
Get directions
Grafenaustrasse 5
Zug, ZG 6300, CH
-
Get directions
3366 N Torrey Pines Ct
#320
San Diego, California 92037, US
Employees at Kiniksa Pharmaceuticals
Updates
-
Kiniksa Reports First Quarter 2026 Financial Results and Recent Portfolio Execution 📄Read the full press release: https://lnkd.in/eFfKDK-B Join our management team for a live webcast and conference call today: 📅Time: 8:30 AM ET 🎥Live Webcast: https://lnkd.in/eFfKDK-B
-
-
📅Save the Date! Join our management team for a conference call and live webcast on Tuesday, April 28th at 8:30 a.m. ET as we report our first quarter 2026 financial results and discuss our recent portfolio execution. 📄Press Release: https://lnkd.in/eFfKDK-B 🎥Live Webcast: https://lnkd.in/eFfKDK-B
-
-
💜 Kiniksa Goes Purple for Sarcoidosis💜 April is Sarcoidosis Awareness Month. Sarcoidosis can affect almost any organ in the body, including the heart. Purple is the internationally recognized color for sarcoidosis, so the Kiniksa team donned our purple to raise awareness with Foundation For Sarcoidosis Research. Join us in wearing purple and share your look! #Sarcoidosis #CardiacSarcoidosis #EverySecondCounts #KiniksaCares #PostInPurple #SarcoidosisAwareness #SeeSarcoidosis
-
-
Join us at #ACC26 on Sunday, March 29, for a panel discussion and Q&A about Evidence-Based Strategies for the Treatment of Recurrent Pericarditis. This Kiniksa-sponsored promotional event is not part of ACC.26, as planned by its Program Committee, and does not qualify for continuing medical education (CME), continuing nursing education (CNE), or continuing education (CE) credit.
-
-
Attending #ACC26, March 28 – 30, in New Orleans? Don’t miss session 1091 and a moderated ePoster, “Sex Difference In The Management Of Recurrent Pericarditis: Insights From The Resonance Registry”
-
-
Attending #ACC26, March 28 – 30, in New Orleans? Don’t miss session 1443 and the poster, “Outcomes From The RESONANCE Patient Registry: Pericarditis Recurrence Risk, Hospitalizations, And ED Visits”
-
-
Attending #ACC26, March 28 – 30, in New Orleans? Visit Kiniksa at Booth 337 to learn about a treatment for recurrent pericarditis.
-
-
📣 Raising Awareness for Rare Disease Day🧬 There are more than 30 million individuals in the United States affected by a rare disease, with an estimated 10,000+ rare diseases. A rare disease is defined as a disease or condition that affects fewer than 200,000 individuals in the United States. Today and every day, we recognize those living with a rare disease or caring for someone with a rare disease, including those impacted by recurrent pericarditis, CAPS (Cryopyrin Associated Periodic Syndrome), and DIRA (Deficiency of Interleukin-1 Receptor Antagonist). We strive to support the rare disease community and Rare Disease Day. Together, we can raise awareness and work to better understand these diseases because Every Second Counts! #RecurrentPericarditis #CAPS #DIRA #RareDisease #KiniksaCares #RareDiseaseDay #EverySecondCounts
-
-
Join our management team for a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2nd at 3:10 p.m. ET. A live webcast and replay will be available at: https://lnkd.in/eFfKDK-B
-